Geneyork debuts generic Deltasone

A new generic corticosteroid to treat arthritis, blood disorders, breathing problems, severe allergies, skin disease, cancer, eye problems, and immune system disorders is now available. Geneyork Pharmaceutical, in collaboration with Lannett is introducing generic Deltasone (Prednisone) tablets in dosage strengths of  1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 50 mg.

Prednisone tablets have a market value of $121 million for 2018, according to IQVIA.

"We are proud to add Prednisone tablets to our growing portfolio of more than 40 specialty products. The launch of Prednisone tablets demonstrates our strong development and partnership capabilities. Geneyork continues to expand its product development portfolio and has secured nine ANDA approvals and has an additional six filed with the FDA. We have also acquired or exclusively in licensed five ANDAs. We are pleased to partner with the Lannett for this launch," said Isaac Liu, Geneyork CEO.

"We look forward to expanding our relationship with Geneyork and launching more products over time. We believe Geneyork selected Lannett as the distributor of the product because of our team's ability to launch products swiftly and execute launch plans well," said Lannett CEO Timothy Crew.